Why the study?
The study was conducted to evaluate the effects of Sacubitril/Valsartan on clinical, laboratory, and echocardiographic parameters and outcomes in a real-world HFrEF population.
Does Sacubitril/Valsartan reduce the composite of cardiac death and HF rehospitalization in patients with HFrEF compared to standard medical therapy?
Does Sacubitril/Valsartan reduce the composite of cardiac death and HF rehospitalization in patients with HFrEF compared to standard medical therapy?
Answers are grounded in this paper and cite their sources.
In a real-world HFrEF population, sacubitril/valsartan significantly reduced the 1-year risk of cardiac death and heart failure rehospitalization while improving echocardiographic parameters compared to standard medical therapy.
The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical, laboratory and echocardiographic parameters and outcomes in a real-world population with heart failure with reduced ejection fraction (HFrEF). This was a prospective observational study enrolling patients with HFrEF undergoing treatment with S/V. The primary outcome was the composite of cardiac death and HF rehospitalization at 12 months follow-up; secondary outcomes were all-cause death, cardiac death and the occurrence of rehospitalization for worsening HF. The clinical outcome was compared with a retrospective cohort of 90 HFrEF patients treated with standard medical therapy. The study included 90 patients (66.1 ± 11.7 years) treated with S/V. The adjusted regression analysis showed a significantly lower risk for the primary outcome (HR:0.31; 95%CI, 0.11-0.83; p = 0.019) and for HF rehospitalization (HR:0.27; 95%CI, 0.08-0.94; p = 0.039) in S/V patients as compared to the control group. A significant improvement in NYHA class, left ventricular ejection fraction, left ventricular end systolic volume and systolic pulmonary arterial pressure was observed up to 6 months. S/V did not affect negatively renal function and was associated with a significantly lower dose of furosemide dose prescribed at 6- and 12-month follow-up. In this study, S/V reduced the risk of HF rehospitalization and cardiac death at 1 year in patients with HFrEF. S/V improved NYHA class, echocardiographic parameters and need of furosemide, and preserved renal function.
No takes yet. Share an insight, caveat, or question.
Polito et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: